Comparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China.

ABSTRACT:

Background

Statins are the cornerstone of lipid-lowering therapies in diabetes and chronic kidney disease (CKD). Rosuvastatin, compared with atorvastatin, is associated with higher risk of kidney impairment in Western populations with diabetes and CKD. However, whether its effects on cardiorenal outcomes can generalise to East Asians remains unknown especially given ethnic differences in statin metabolism. We aimed to compare the risk associations of rosuvastatin versus atorvastatin for cardiovascular-renal outcomes in Chinese people with diabetes across CKD stages.

Methods

For this target trial emulation, we included a propensity-score overlap-weighted cohort of 106,677 patients (aged 18+ years) with diabetes (type 1 or type 2) in Hong Kong in 2002-2019, comprising 13,737 n

SUBMITTER: Huang Y 

PROVIDER: S-EPMC12774773 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature